Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tongfu capsules fluid is a Traditional Chinese Medicine (TCM) formulation developed by the Second Affiliated Hospital of Guangzhou University of Chinese Medicine (also known as Guangdong Provincial Hospital of Chinese Medicine). It is administered as a retention enema for the prevention of stroke-associated pneumonia (SAP) in high-risk acute stroke patients. The treatment is based on the TCM principle of "Lung being connected with Large Intestine," which suggests that dredging the intestines (Tongfu) can help clear heat and toxins from the lungs. The preparation is derived from Tongfu capsules, which typically contain botanical ingredients such as *Rheum palmatum* (Da Huang) intended to promote gastrointestinal motility, reduce abdominal distension, and modulate systemic inflammatory responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tongfu capsules fluid.